The TNF-a inhibitors, including etanercept and infliximab, have been disappointing in the treatment of dermatomyositis
More invasive procedures can be used for patients with moderate-to-severe symptoms of BPH, particularly for patients who have not responded to pharmacologic therapy (McVary 2011)
231 Loss of PINK1-Parkin exacerbates KRAS-driven pancreatic tumorigenesis, 230 whereas PINK1 acts as a tumor suppressor in glioblastoma by reducing ROS and HIF activation

Molecular mechanisms of cutaneous ageing To interpret the effects of dermatological peptides, the molecular alterations of cutaneous ageing must be understood: Intrinsic ageing (chronological) Decreased collagen synthesis by fibroblasts (1% per year after 30) AGE accumulation (Advanced Glycation End-products) by non-enzymatic glycation Fibroblastic senescence with SASP (Senescence-Associated Secretory Phenotype), chronic pro-inflammatory secretion Dermal atrophy , reduced vascularisation, loss of subcutaneous adipocytes Extrinsic ageing (photoageing) UV-B damage : cyclobutane pyrimidine dimers, keratinocyte DNA alteration UV-A and oxidative stress : ROS, lipid peroxidation, protein carbonylation MMP overexpression (MMP-1, MMP-3, MMP-9) via AP-1 activation, degrading collagen and elastin Solar elastosis : accumulation of degraded and dystrophic elastin in the dermis Dermatological peptides act at different levels of these cascades: anabolic stimulation (GHK-Cu, Matrixyl), catabolic inhibition (MMP modulation), anti-oxidant protection (GHK-Cu), inflammatory signalling modulation

The faster reaction with GSSG might reflect the simultaneous interaction of the substrate with both glutathione interaction sites